Cirio advises Intervacc in connection with its rights issue

Cirio is acting as legal advisor to Intervacc AB (publ) in connection with its rights issue of SEK 225 million. The rights issue is secured to approximately 80 percent through subscription and guarantee commitments. The rights issue is subject to approval by an extraordinary general meeting to be held on 31 January 2025.

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its proprietary technology platform with fused recombinant proteins. The company’s share is listed on Nasdaq First North Growth Market.

Cirio’s team is led by Maria Arnoldsson (Capital Markets and Public M&A) and Per Hedman (Life sciences), with assistance from Fredrik Billing and Selma Didriksson Fröjd (Capital Markets and Public M&A), among others.

For more information, please contact: